Effects of streptovaricins and their degradation products on infectivity of Rauscher leukemia virus.
The virucidal effects of streptovaricin (Sv) A, SvC, SvD, streptoval (Sval) C, Sval Fc, and streptovarone were evaluated by incubation of the drug with Rauscher leukemia virus (RLV) at 37 degrees C for 60 minutes prior to dillution and addition to cells (in vitro assay) or before ip injection into animals (in vivo assay). The in vitro and in vivo assays were plaque formation and splenomegaly, respectively. A dose-related effect was observed with all six compounds with the in vitro assay. On an equimolar basis, the Sv degradation products, i.e., Sval C, Sval Fc, and streptovarone were most inhibitory, followed by SvD; SvA and SvC were least active. At 0.0625 mumoles, the three Sv degradation products inactivated over 90% of the RLV. Similar results were obtained through the in vivo assay. At 0.06 mumoles, streptovarone, Sval C, and SvD showed 78,62, and 29% inhibition of splenomegaly, respectively; SvA and SvC were essentially inactive. A direct relationship was observed between inhibition on RNA-directed DNA polymrase of RLV by these compounds and their virucidal effects. No drug given at the time of injection, however, showed any significant effect on virus infective processes in vitro or in vivo. The reason for the lack of therapeutic effects of these compounds is discussed.
D000818:Animals; D000998:Antiviral Agents; D002478:Cells, Cultured; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000209:etiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011925:Rauscher Virus / Q000187:drug effects* / Q000201:enzymology; D018894:Reverse Transcriptase Inhibitors; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D013310:Streptovaricin / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D013310:Streptovaricin